The aim of the present study was to determine whether cleavage of the Her-2/neu ECD is correlated with overall tyrosine kinase activity in vivo and might therefore constitute a clinically relevant ligand-independent mechanism for the activation of Her-2/neu in breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.